Paul Stamets discusses strain 65 of Agarikon (Fomitopsis officinalis), a rare medicinal mushroom with a long history of use in Europe and North America. Stamets has assembled the world's largest culture library of this species—65 strains total—and is using whole genome sequencing to identify a "super strain" with potent anti-inflammatory, antiviral, and immunomodulatory properties. The goal is to find a strain that could help humanity fortify immune defenses against pathogens, much like Mary Hunt's penicillin discovery saved millions of lives. Stamets treats this work as part of a centuries-long chain of knowledge custody, particularly urgent since Agarikon grows only in old-growth forests and faces extinction in Europe.
Why Did Ancient Cultures Revere Agarikon?
Agarikon's appeal across cultures goes deeper than mere medicinal potency. Stamets points out that the mushroom naturally takes on anthropomorphic forms—shapes that resemble human anatomy. "It takes on anthropomorphic forms oftentimes resemble that of humans," he explains, noting "here's two legs, a little cute little butt." These distinctive shapes made the mushroom attractive for carving into figurative objects that were revered in many cultures. The combination of unusual form and proven medicinal power created a natural intersection between aesthetic interest and therapeutic application, which may explain why ancestors across Europe and North America were drawn to it as both a spiritual and healing artifact.
This dual appeal—form plus function—underscores a principle Stamets returns to throughout his work: nature's design often carries both symbolic and biochemical significance. The mushroom's resemblance to human figures was not incidental to its cultural adoption; it was a doorway into deeper engagement with its healing properties.
How Did Strain 65 Enter the Research Collection?
The acquisition of strain 65 reflects the conservation mission driving Stamets's broader research. An environmentalist named Marty contacted him with an unusual urgency: the old-growth forest where Agarikon grew was scheduled for clear-cutting within days. Stamets's initial instinct was to urge preservation—"please don't pick it"—but when faced with the reality of imminent forest loss, he shifted his approach. "The forest gonna be clear-cut in the next few days, and I said okay, good reason," Stamets recalls.
Marty, an experienced climber, undertook a dangerous ascent to harvest a single specimen. Rather than grow it in its original habitat or attempt to transplant it, Stamets employed a technique fundamental to his work: tissue cloning. "We then took a small piece of tissue we cloned it so we saved the strain even though now the forest has been cut." This methodological choice was deliberate—by isolating a living culture from the wild specimen, Stamets could preserve the genetic lineage indefinitely, creating an insurance policy against extinction. Strain 65 now lives as a living archive, a backup copy of biodiversity that might otherwise be lost to land clearing.
What Makes Agarikon Biochemically Unique?
Agarikon possesses a rare convergence of medicinal properties that few medicinal mushrooms display simultaneously. Stamets describes this combination as "a unique combination of attributes": anti-inflammatory activity, antiviral potency, and immunomodulatory effects. These three properties working together allow the mushroom to help humans "fortify their immune system to resist pathogens." Unlike plants or fungi with a single therapeutic strength, Agarikon addresses immune function from multiple angles—reducing excessive inflammation, inhibiting viral replication, and tuning immune response itself.
This layered therapeutic profile is why Stamets views strain hunting as potentially high-impact. Different strains of the same species can vary significantly in their bioactive compound profiles. One strain might be stronger in antiviral compounds; another might excel in anti-inflammatory polysaccharides. By cultivating and screening 65 different strains, Stamets is not seeking a minor improvement but rather the discovery of a strain whose combination of properties is genuinely transformative—a "super strain" capable of addressing immune challenges at scale.
What Is the "Super Strain" Model and Why Does It Matter?
Stamets frames his search through the historical precedent of Mary Hunt and penicillin. In 1943, Hunt, a laboratory technician working in Chicago, discovered a moldy cantaloupe contamination in a petri dish. Though Alexander Fleming had discovered penicillin's antibacterial properties in 1928, it was Hunt's specific mold strain—isolated from her cantaloupe—that proved suitable for mass cultivation and commercialization. "It was her strain of the moldy cantaloupe that led her to a super strain that allowed for the commercialization of penicillin to save literally millions of lives."
This historical analogy reveals the scaling problem in natural product research. Discovery of a compound's existence is not the same as discovery of a production-ready variant. Hunt's contribution was finding the strain that worked—the genetic line whose growth rate, yield, and stability made industrial manufacture possible. Stamets applies the same logic to Agarikon: the species has known medicinal properties, but among the 65 strains now in culture, one might possess the bioactive profile and robustness needed to become a meaningful therapeutic intervention at population scale.
He acknowledges the uncertainty: "Will this little guy be a super strain we don't know." But the methodology is sound. By conducting whole genome sequencing on each strain and comparing their anti-inflammatory, antiviral, and immunomodulatory activity, Stamets's team creates a searchable database of microbial diversity. One strain's genetic makeup will eventually reveal why it outperforms the others, a discovery that could unlock the pathway to cultivation and clinical development.
Why Is Agarikon Facing Extinction?
Agarikon exists in what Stamets calls a "bridge of extinction in Europe." The mushroom grows exclusively in old-growth forests—specifically on ancient trees in their native habitat. Old-growth forests are disappearing at an accelerating rate due to logging, development, and land conversion. As these forests vanish, wild Agarikon populations vanish with them.
This ecological fragility explains the urgency of Stamets's work. Unlike cultivated medicinal plants, which can be propagated in agricultural systems, Agarikon cannot be conventionally farmed. Its dependence on specific forest conditions means that once wild populations are gone, the species is effectively lost unless living cultures are preserved in laboratories. Stamets's culture library is not a backup file; it is a biological archive of the last remaining genetic diversity of this species. "We want to collect a genomic library of great microdiversity" precisely because the wild source cannot be assumed to exist in a few years.
What Is the "Chain of Custody of Knowledge" Stamets Describes?
Stamets positions his work within a historical continuum stretching back centuries. "I feel it's a thread of knowledge through the centuries through thousands of years," he explains. Indigenous peoples, medieval herbalists, and modern mycologists have all engaged with Agarikon, each generation learning something new about its properties and applications. Stamets sees himself not as the originator of this knowledge but as a temporary custodian of it.
"I'm just one micronaut of many in this long chain of custody of knowledge to help the commons." The use of "micronaut"—a term borrowed from science fiction meaning a pilot of microscopic scale—is deliberate. Stamets frames his individual contribution as tiny, even humble, within the vastness of ecological and human knowledge. His role is to preserve, advance, and pass forward what previous cultures discovered and what future generations will need. This custodial view reframes research not as individual achievement but as a relay race spanning centuries, with each participant responsible for handing the baton forward in better condition than they received it.
How Does Whole Genome Sequencing Enable Strain Selection?
The integration of genomic sequencing into Stamets's screening process represents the application of modern biotechnology to traditional ethnobotanical knowledge. Rather than relying solely on bioassays (testing anti-inflammatory or antiviral activity in lab conditions), the team now sequences the complete genetic code of each strain. This allows researchers to compare not just the phenotypic results—what the strain does—but the genotypic basis for those results—why it does it.
A strain with exceptional antiviral properties, for example, might express a unique cluster of genes encoding novel antimicrobial peptides or polysaccharides. Sequencing makes these genetic signatures visible. Over time, as multiple strains are sequenced and their bioactivity compared, patterns emerge: strain X lacks genes present in strain Y, and strain Y consistently shows stronger antiviral activity. This correlation between genetic content and therapeutic output creates a rational basis for identifying the super strain before it is even scaled for production. The candidate has already revealed its promise at the molecular level.
Where to Go From Here
For those interested in following this research, Stamets's ongoing strain library expansion and sequencing project continues under his mycological work. The implications extend beyond Agarikon: this model of systematic strain hunting, cultural preservation, and genomic screening could apply to dozens of other rare medicinal fungi and plants facing extinction. As climate change and land conversion accelerate habitat loss, the race to catalog and preserve microbial and fungal diversity becomes increasingly urgent.
The question Stamets poses is not merely scientific but ethical: if a super strain of Agarikon exists among these 65 cultures, and if its therapeutic potential could benefit millions, what responsibility do we bear to find it before the source populations disappear entirely? His work suggests that the answer lies not in either/or thinking—preservation or development—but in both: save the species while screening it for maximum human benefit, creating a feedback loop where conservation and medicine reinforce each other.
